Aimmune Therapeutics Inc. (AIMT) Stock Price Up 5.4%
Aimmune Therapeutics Inc. (NASDAQ:AIMT)’s share price rose 5.4% during trading on Tuesday . The company traded as high as $15.52 and last traded at $15.50, with a volume of 138,297 shares trading hands. The stock had previously closed at $14.70.
AIMT has been the subject of a number of research reports. Zacks Investment Research upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Friday, May 20th. Bank of America Corp. restated a “buy” rating on shares of Aimmune Therapeutics in a research note on Monday, May 16th. Wedbush restated a “buy” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a research note on Wednesday, August 24th. Credit Suisse Group AG restated a “buy” rating and issued a $35.00 target price on shares of Aimmune Therapeutics in a research note on Friday, August 19th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $38.00 target price on shares of Aimmune Therapeutics in a research note on Wednesday, June 29th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $32.75.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/06/aimmune-therapeutics-inc-aimt-stock-price-up-5-4/
The company’s market capitalization is $664.23 million. The company’s 50-day moving average price is $13.03 and its 200 day moving average price is $13.77.
Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.01. Analysts predict that Aimmune Therapeutics Inc. will post ($1.71) EPS for the current year.
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.